Oppenheimer analyst Mark Breidenbach reiterated a Buy rating on Aduro BioTech (ADRO) today. The company’s shares opened today at $3.90.
According to TipRanks.com, Breidenbach is a 3-star analyst with an average return of 1.3% and a 43.6% success rate. Breidenbach covers the Healthcare sector, focusing on stocks such as Iovance Biotherapeutics Inc, Alpine Immune Sciences Inc, and Global Blood Therapeutics.
Currently, the analyst consensus on Aduro BioTech is a Strong Buy with an average price target of $7.
See today’s analyst top recommended stocks >>
The company has a one-year high of $9.85 and a one-year low of $2.34. Currently, Aduro BioTech has an average volume of 921.4K.
Based on the recent corporate insider activity of 28 insiders, corporate insider sentiment is negative on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Aduro BioTech, Inc. is a clinical-stage immunotherapy company, which engages in the discovery, development, and commercialization of therapies that transform the treatment of diseases, including cancer. Its technology platforms include STING Pathway Activator, B-select monoclonal antibody, and LADD, or Live, Attenuated, Double-Deleted Listeria monocytogenes.
